Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2017New England Journal of MedicineOpen Access

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDavid P. CarboneAstraZeneca (United Kingdom)MRMartin ReckGerman Center for Lung Research
Luis Paz‐Ares
Luis Paz‐AresUniversidad Complutense de Madrid

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Carbone et al. (2017) studied this question.

synapsesocial.com/papers/6a5c3e5fcf4f37ea7699edbahttps://doi.org/10.1056/nejmoa1613493
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer2013 · 377 citations
  2. 2NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.20162016 · 739 citations
  3. 3Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer2015 · 8,069 citations
  4. 4Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,641 citations
  5. 5Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer2008 · 3,235 citations